The QIBA profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy

Paul E. Kinahan; Eric S. Perlman; John J. Sunderland; Rathan Subramaniam; Scott D. Wollenweber; Timothy G. Turkington; Martin A. Lodge; Ronald Boellaard; Nancy A. Obuchowski; Richard L. Wahl

doi:10.1148/radiol.2019191882

The QIBA profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy

Paul E. Kinahan, Eric S. Perlman, John J. Sunderland, Rathan Subramaniam, Scott D. Wollenweber, Timothy G. Turkington, Martin A. Lodge, Ronald Boellaard, Nancy A. Obuchowski, Richard L. Wahl

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUV_max) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%–12%. Second, a measured increase in SUV_max of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.

Original language	English (US)
Pages (from-to)	647-657
Number of pages	11
Journal	RADIOLOGY
Volume	294
Issue number	2
DOIs	https://doi.org/10.1148/radiol.2019191882
State	Published - 2020

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1148/radiol.2019191882

Cite this

@article{20aaf4c06c5a4c529e126df123e2e0db,

title = "The QIBA profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy",

abstract = "The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUVmax) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%–12%. Second, a measured increase in SUVmax of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.",

author = "Kinahan, {Paul E.} and Perlman, {Eric S.} and Sunderland, {John J.} and Rathan Subramaniam and Wollenweber, {Scott D.} and Turkington, {Timothy G.} and Lodge, {Martin A.} and Ronald Boellaard and Obuchowski, {Nancy A.} and Wahl, {Richard L.}",

note = "Publisher Copyright: {\textcopyright} RSNA, 2020",

year = "2020",

doi = "10.1148/radiol.2019191882",

language = "English (US)",

volume = "294",

pages = "647--657",

journal = "RADIOLOGY",

issn = "0033-8419",

publisher = "Radiological Society of North America Inc.",

number = "2",

}

TY - JOUR

T1 - The QIBA profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy

AU - Kinahan, Paul E.

AU - Perlman, Eric S.

AU - Sunderland, John J.

AU - Subramaniam, Rathan

AU - Wollenweber, Scott D.

AU - Turkington, Timothy G.

AU - Lodge, Martin A.

AU - Boellaard, Ronald

AU - Obuchowski, Nancy A.

AU - Wahl, Richard L.

PY - 2020

Y1 - 2020

N2 - The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUVmax) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%–12%. Second, a measured increase in SUVmax of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.

AB - The Quantitative Imaging Biomarkers Alliance (QIBA) Profile for fluorodeoxyglucose (FDG) PET/CT imaging was created by QIBA to both characterize and reduce the variability of standardized uptake values (SUVs). The Profile provides two complementary claims on the precision of SUV measurements. First, tumor glycolytic activity as reflected by the maximum SUV (SUVmax) is measurable from FDG PET/CT with a within-subject coefficient of variation of 10%–12%. Second, a measured increase in SUVmax of 39% or more, or a decrease of 28% or more, indicates that a true change has occurred with 95% confidence. Two applicable use cases are clinical trials and following individual patients in clinical practice. Other components of the Profile address the protocols and conformance standards considered necessary to achieve the performance claim. The Profile is intended for use by a broad audience; applications can range from discovery science through clinical trials to clinical practice. The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to outline future needs and potential developments.

UR - http://www.scopus.com/inward/record.url?scp=85080847353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080847353&partnerID=8YFLogxK

U2 - 10.1148/radiol.2019191882

DO - 10.1148/radiol.2019191882

M3 - Article

C2 - 31909700

AN - SCOPUS:85080847353

SN - 0033-8419

VL - 294

SP - 647

EP - 657

JO - RADIOLOGY

JF - RADIOLOGY

IS - 2

ER -

The QIBA profile for FDG PET/CT as an imaging biomarker measuring response to cancer therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this